Navigation Links
Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
Date:7/31/2008

PALO ALTO, Calif., July 31 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that it will move its corporate headquarters from Palo Alto, Calif. to the Chicago, Ill., area.

"The relocation will help us continue growing, extend our opportunities for partnerships and conduct business in one of the most dynamic markets in the country," said Timothy P. Walbert, president and chief executive officer of Horizon. "Chicago has all the elements to become a major life-science hub, but it's still rivaled by its bi-coastal counterparts. We wanted to relocate here to be an integral part of the market growth as well as leverage the existing market opportunities to grow our business."

The company will begin operations in its new headquarters in early August at the Illinois Science and Technology Park in Skokie, Ill., which formerly housed the Searle and then subsequently Pharmacia and Pfizer research and development offices. Horizon has approximately 50 full-time employees and consultants.

Mr. Walbert, who was recently named president and chief executive officer of Horizon and has approximately 20 years of proven experience launching and commercializing blockbuster drugs in the pain and arthritis fields, is focusing the Company's efforts on meeting the needs of arthritis and pain sufferers, specifically with its investigational compound HZT-501, a novel proprietary formulation of ibuprofen combined with famotidine in a single pill currently in Phase 3 clinical trials. Because approximately 25 percent of NSAID users may develop stomach ulcers, HZT-501 may offer patients effective pain relief with the confidence of GI-protection. Horizon expects to have data from the HZT-501 Phase 3 trials in fourth quarter of this year.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the trea
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences ... an oncology company that identifies,develops and commercializes differentiated ... hosted by Mr. David Allan, Chairman and CEO, ... the professional investment,community are invited to discuss the ...
... Aug. 5 Marinus Pharmaceuticals, a,developer of specialty ... has appointed John Krayacich as president,and chief executive ... company,s drug and business development for ganaxolone, an ... chelerythrine, a pre-clinical,schizophrenia candidate., Mr. Krayacich brings ...
... Aug. 5 NeoStem, Inc. (Amex: NBS ),announced today ... Coral Gables, a suburb of Miami, is targeted to open ... with CelVida,LLC. With the opening of this center, NeoStem has ... to a large U.S. market as well as a,growing sophisticated ...
Cached Biology Technology:NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER 2Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 2Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 3Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 4NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide 2NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide 3
(Date:9/18/2014)... Miranda, a small, icy moon of Uranus, is one ... the solar system. Despite its relatively small size, Miranda ... that resulted in the formation of at least three ... coronae. , These coronae are visible in Miranda,s ... km across. Arden corona, the largest, has ridges and ...
(Date:9/18/2014)... Wis. No matter how many times it,s ... social, communicating creatures. , But by using ... organisms radically alter their behavior to suit their ... of them are present, and act accordingly. , ... millions, it may change from innocuous to pathogenic, ...
(Date:9/18/2014)... 18, 2014 -- Arizona turned its newborn screening program into ... short months, earning it the first-ever Newborn Screening Quality Award ... Dimes presented Will Humble, M.P.H., Arizona,s Department of Health Services ... Mr. Humble established a policy of full transparency for the ... blood samples to the lab for analysis, and set a ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... out closely related species and managing each type on ... management system. Some species, like the two types ... behavior that differentiation can be challenging. Conservation researchers at ... developed a mechanism for identifying these reclusive species from ...
... (Jan 3, 2012) Immune system abnormalities that mimic those ... amyloid precursor protein (APP), reports a research team from the ... Child Development Center. The study, conducted with mouse ... fragment circulating in the blood could explain the aberrations in ...
... Philadelphia, PA, January 3 For the ... Association for Echocardiography and the American Society of ... three-dimensional echocardiography (3DE). ,The EAE/ASE Recommendations for Image ... in the January 2012 issue of the ...
Cached Biology News:Autism may be linked to abnormal immune system characteristics and novel protein fragment 2EAE/ASE 3D echocardiography image acquisition recommendations 2
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... unique quantitative and qualitative capabilities of the ... LC/MS/MS Systems with the new Tempo nano ... a rapid solution for high sensitivity validation ... extensive sample preparation with high instrument selectivity ...
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class performance ... QA/QC software, Agilents world-renowned support and columns, ... and supplies--a combination that lets you reach ... based on dependable data. The Agilent 6820 ...
Biology Products: